GURUFOCUS.COM » STOCK LIST » Healthcare » Medical Devices & Instruments » Zomedica Corp (AMEX:ZOM) » Definitions » Current Ratio

Zomedica (Zomedica) Current Ratio : 11.06 (As of Dec. 2023)


View and export this data going back to 2016. Start your Free Trial

What is Zomedica Current Ratio?

The current ratio is a liquidity ratio that measures a company's ability to pay short-term obligations. It is calculated as a company's Total Current Assets divides by its Total Current Liabilities. Zomedica's current ratio for the quarter that ended in Dec. 2023 was 11.06.

Zomedica has a current ratio of 11.06. It indicates the company may not be efficiently using its current assets or its short-term financing facilities. This may also indicate problems in working capital management.

The historical rank and industry rank for Zomedica's Current Ratio or its related term are showing as below:

ZOM' s Current Ratio Range Over the Past 10 Years
Min: 0.87   Med: 14.74   Max: 46.18
Current: 11.06

During the past 11 years, Zomedica's highest Current Ratio was 46.18. The lowest was 0.87. And the median was 14.74.

ZOM's Current Ratio is ranked better than
92.38% of 866 companies
in the Medical Devices & Instruments industry
Industry Median: 2.725 vs ZOM: 11.06

Zomedica Current Ratio Historical Data

The historical data trend for Zomedica's Current Ratio can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Zomedica Current Ratio Chart

Zomedica Annual Data
Trend Feb14 Feb15 Feb16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
Current Ratio
Get a 7-Day Free Trial Premium Member Only Premium Member Only 0.87 31.48 46.18 15.81 11.06

Zomedica Quarterly Data
Mar19 Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23
Current Ratio Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 15.81 15.14 19.37 17.12 11.06

Competitive Comparison of Zomedica's Current Ratio

For the Medical Devices subindustry, Zomedica's Current Ratio, along with its competitors' market caps and Current Ratio data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Zomedica's Current Ratio Distribution in the Medical Devices & Instruments Industry

For the Medical Devices & Instruments industry and Healthcare sector, Zomedica's Current Ratio distribution charts can be found below:

* The bar in red indicates where Zomedica's Current Ratio falls into.



Zomedica Current Ratio Calculation

The current ratio is mainly used to give an idea of the company's ability to pay back its short-term liabilities with its short-term assets.

Zomedica's Current Ratio for the fiscal year that ended in Dec. 2023 is calculated as

Current Ratio (A: Dec. 2023 )=Total Current Assets (A: Dec. 2023 )/Total Current Liabilities (A: Dec. 2023 )
=99.882/9.032
=11.06

Zomedica's Current Ratio for the quarter that ended in Dec. 2023 is calculated as

Current Ratio (Q: Dec. 2023 )=Total Current Assets (Q: Dec. 2023 )/Total Current Liabilities (Q: Dec. 2023 )
=99.882/9.032
=11.06

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Zomedica  (AMEX:ZOM) Current Ratio Explanation

The current ratio can give a sense of the efficiency of a company's operating cycle or its ability to turn its product into cash. Companies that have trouble getting paid on their receivables or have long inventory turnover can run into liquidity problems because they are unable to alleviate their obligations. Because business operations differ in each industry, it is always more useful to compare companies within the same industry.

Acceptable current ratios vary from industry to industry and are generally between 1 and 3 for healthy businesses.

The higher the current ratio, the more capable the company is of paying its obligations. A ratio under 1 suggests that the company would be unable to pay off its obligations if they came due at that point. While this shows the company is not in good financial health, it does not necessarily mean that it will go bankrupt - as there are many ways to access financing - but it is definitely not a good sign.

If all other things were equal, a creditor, who is expecting to be paid in the next 12 months, would consider a high current ratio to be better than a low current ratio, because a high current ratio means that the company is more likely to meet its liabilities which fall due in the next 12 months.


Zomedica Current Ratio Related Terms

Thank you for viewing the detailed overview of Zomedica's Current Ratio provided by GuruFocus.com. Please click on the following links to see related term pages.


Zomedica (Zomedica) Business Description

Traded in Other Exchanges
N/A
Address
100 Phoenix Drive, Suite 125, Ann Arbor, MI, USA, 48108
Zomedica Corp is a veterinary health company creating products for companion animals (canine, feline and equine) by focusing on the unmet needs of clinical veterinarians. The company's product portfolio includes diagnostics and therapeutics that emphasize patient health and practice health. The company is currently focused on the final development and commercialization of its TRUFORMA platform, which detects thyroid disorders in dogs & cats and adrenal disorders in dogs. Its operations are comprised of two reportable segments: Diagnostic & Therapeutics. It earns the majority of revenue from the therapeutics segment.
Executives
Johnny D Powers director C/O ZOMEDICA CORP., 100 PHOENIX DRIVE, SUITE 125, ANN ARBOR MI 48018
Heaton Larry C Ii officer: President C/O ZOMEDICA CORP., 100 PHOENIX DRIVE, SUITE 125, ANN ARBOR MI 48018
Russell Kevin Klass officer: Vice President of Sales C/O ZOMEDICA CORP, PHOENIX DRIVE, SUITE 125, ANN ARBOR MI 48108
Peter Donato officer: Chief Financial Officer 9172 ETON AVENUE, CHATSWORTH CA 91311
Pamela Nichols director 14841 EAST WILDCAT DR., SCOTTSDALE AZ 85262
Karen Dehaan-fullerton officer: Chief Counsel and Secretary C/O ZOMEDICA CORP, 100 PHOENIX DRIVE, SUITE 125, ANN ARBOR MI 48018
Anthony K Blair officer: Chief Operating Officer NEOPROBE CORPORATION, 425 METRO PLACE NORTH #300, DUBLIN OH 43017
Adrian Lock officer: VP and General Manager C/O ZOMEDICA CORP, 100 PHOENIX DRIVE, SUITE 125, ANN ARBOR MI 48018
Sean Whelan director C/O ZOMEDICA CORP., 100 PHOENIX DRIVE, SUITE 125, ANN ARBOR MI 48108
Robert Cohen officer: Interim CEO C/O ZOMEDICA CORP., 100 PHOENIX DRIVE, SUITE 125, ANN ARBOR MI 48108
Ann Cotter officer: Chief Financial Officer & Sec. C/O ZOMEDICA PHARMACEUTICALS CORP., 100 PHOENIX DRIVE, SUITE 180, ANN ARBOR MI 48108
Stephanie Morley officer: COO & VP of Product Dev C/O ZOMEDICA CORP., 100 PHOENIX DRIVE, SUITE 125, ANN ARBOR MI 48108
Christopher Ross Macleod director C/O ZOMEDICA CORP., 100 PHOENIX DRIVE, SUITE 125, ANN ARBOR MI 48018
Christopher Wolfenberg director C/O ZOMEDICA PHARMACEUTICALS CORP, 100 PHOENIX DRIVE, SUITE 180, ANN ARBOR MI 48108
Gerald Jr Solensky director, 10 percent owner, officer: President and CEO C/O ZOMEDICA PHARMACEUTICALS CORP., 100 PHOENIX DRIVE, SUITE 190, ANN ARBOR MI 48108

Zomedica (Zomedica) Headlines

From GuruFocus

Zomedica Provides Corporate Update

By ACCESSWIRE 09-14-2023